| Phase 110 trials |
|
Phase 1
|
NCT03944902 |
Sep 2021 → Jan 2022 |
ovarian cancer |
University of Alabama at Birmingham |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT04250545 |
Oct 2020 → Nov 2025 overdue |
metastatic malignant neoplasm in the brain, neoplastic meningitis, non-small cell lung carcinoma |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT04607512 |
Oct → Dec 2020 |
— |
Calithera Biosciences, Inc |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04540965 |
Sep → Dec 2020 |
— |
Calithera Biosciences, Inc |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03798678 |
Jul 2019 → Nov 2023 overdue |
plasma cell myeloma |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT03528642 |
May 2019 → Sep 2026 expected |
astrocytoma, IDH-mutant, grade 2, astrocytoma, IDH-mutant, grade 3 |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT02944435 |
Oct → Nov 2016 |
— |
Calithera Biosciences, Inc |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02071927 |
Mar 2014 → Oct 2016 |
acute lymphoblastic leukemia, acute myeloid leukemia |
Calithera Biosciences, Inc |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02071888 |
Feb 2014 → Apr 2016 |
T-cell non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, plasma cell myeloma |
Calithera Biosciences, Inc |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02071862 |
Feb 2014 → Mar 2019 |
gastrointestinal stromal tumor, mesothelioma, non-small cell lung carcinoma, renal cell carcinoma +1 |
Calithera Biosciences, Inc |
Completed
|
No outcome recorded
|
| Phase 1/27 trials |
|
Phase 1/2
|
NCT07223528 |
Aug 2026 → Sep 2028 expected |
pulmonary hypertension |
Chan, Stephen, MD, PhD |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT03831932 |
Mar 2020 → Jun 2024 overdue |
non-small cell lung carcinoma |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT03875313 |
May 2019 → Jul 2020 |
clear cell renal carcinoma, colorectal cancer, triple-negative breast carcinoma |
Calithera Biosciences, Inc |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT03047993 |
Nov 2017 → Mar 2023 |
acute myeloid leukemia with multilineage dysplasia, chronic myelomonocytic leukemia, myelodysplastic syndrome |
M.D. Anderson Cancer Center |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT03263429 |
Aug 2017 → Aug 2023 |
colorectal cancer |
Vanderbilt-Ingram Cancer Center |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT02861300 |
Sep 2016 → Jan 2023 |
colon carcinoma, rectal cancer |
David Bajor, MD |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT02771626 |
Aug 2016 → Apr 2020 |
clear cell renal carcinoma, melanoma, non-small cell lung carcinoma |
Calithera Biosciences, Inc |
Terminated
|
No outcome recorded
|
| Phase 26 trials |
|
Phase 2
|
NCT05521997 |
Jul 2026 → Oct 2032 expected |
cervical carcinoma |
Washington University School of Medicine |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04824937 |
Jul → Dec 2021 |
metastatic prostate carcinoma |
Massachusetts General Hospital |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT04265534 |
Jul 2020 → Nov 2021 |
non-small cell lung carcinoma |
Calithera Biosciences, Inc |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT03872427 |
Dec 2019 → Oct 2023 overdue |
malignant peripheral nerve sheath tumor, metastatic malignant neoplasm |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT03428217 |
Apr 2018 → Aug 2020 |
clear cell renal carcinoma |
Calithera Biosciences, Inc |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03057600 |
May 2017 → Nov 2019 |
triple-negative breast carcinoma |
Calithera Biosciences, Inc |
Completed
|
No outcome recorded
|